Trials / Completed
CompletedNCT02899988
A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis
A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo- Controlled Study of LY3074828 in Subjects With Moderate-to- Severe Plaque Psoriasis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 205 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the efficacy of the study drug mirikizumab in participants with moderate to severe plaque psoriasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mirikizumab | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2016-09-14
- Primary completion
- 2017-06-19
- Completion
- 2019-05-08
- First posted
- 2016-09-14
- Last updated
- 2020-06-18
- Results posted
- 2020-06-18
Locations
40 sites across 6 countries: United States, Canada, Germany, Japan, Poland, Puerto Rico
Source: ClinicalTrials.gov record NCT02899988. Inclusion in this directory is not an endorsement.